Get In Touch
Have any questions or comments about the content you see on this page?
Our News
January 3, 2019
Our CEO John Maraganore, Ph.D. talks with Chemical & Engineering News' Lisa Jarvis and Ryan Cross on this episode of C&EN's Stereo Chemistry podcast.
From C&EN: "RNA should be a terrible drug target. It’s long, noodle-like structure lacks the nooks and crannies that small molecule drugs use to grab onto proteins and thereby control them. But a decades-old disregard for RNA is starting to change. In August 2018, the US Food and Drug Administration approved the first-ever RNA interference (RNAi) drug, which uses a double-stranded RNA molecule to prevent the production of disease-related proteins. In the past two years, several startups have launched to show that some RNAs can, just like proteins, be drugged with small molecules. And a third group of companies recently emerged with plans to drug proteins that make modifications to RNA, part of the budding field of epitranscriptomics. In this episode, C&EN visits Alnylam Pharmaceuticals, Novartis, and Accent Therapeutics to discuss these three strategies, and to understand how RNA-modulating therapies will compete in the wider world of drug discovery."
Perspectives, Podcasts, RNAi, Leadership, Biotech, John Maraganore
Have any questions or comments about the content you see on this page?
The following content may not be associated with Alnylam Pharmaceuticals.
Links to all outside sites are provided as a reference for our visitors.
Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.
Proceed to Site